NCT05885555 - A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 16, 2023

Primary Completion Date

February 5, 2025

Study Completion Date

March 19, 2029

Conditions

Primary Immune Thrombocytopenia (ITP)

Interventions

BIOLOGICAL

Ianalumab

Intravenous infusion, prepared from concentrate solution

Trial Locations (24)

2605

Novartis Investigative Site, Garran

3004

Novartis Investigative Site, Melbourne

10126

Novartis Investigative Site, Torino

22030

Novartis Investigative Site, Edirne

31059

Novartis Investigative Site, Toulouse

34098

Novartis Investigative Site, Istanbul

35100

Novartis Investigative Site, Izmir

35392

Novartis Investigative Site, Giessen

41380

Novartis Investigative Site, Kocaeli

80100

Novartis Investigative Site, Johor Bahru

100730

Novartis Investigative Site, Beijing

250012

Novartis Investigative Site, Jinan

430022

Novartis Investigative Site, Wuhan

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Med Center, Boston

C1181ACH

Novartis Investigative Site, CABA

01307

Novartis Investigative Site, Dresden

07740

Novartis Investigative Site, Jena

40-519

Novartis Investigative Site, Katowice

06591

Novartis Investigative Site, Seoul

08003

Novartis Investigative Site, Barcelona

09100

Novartis Investigative Site, Aydin

G31 2ER

Novartis Investigative Site, Glasgow

W12 0HS

Novartis Investigative Site, London